TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07454187: A Phase 1b/2 Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SG2918 for Injection in Patients With Relapsed/Refractory Multiple Myeloma

Sponsor: Hangzhou Sumgen Biotech Co., Ltd. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 40 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$8,875,020

Rescue Site Savings

+$5,851,230

Unlock Full NCT07454187 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07454187 Rescue Dossier →